Here is a snapshot of their company. A lot is coming from this multi-national powerhouse.
OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies.
They intend to leverage their global commercialization expertise to pursue acquisitions of commercial businesses that will both drive their growth and provide geographically diverse sales and distribution opportunities. OPKO has and may continue to make investments in other early stage companies that they perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder.
Since 2009, OPKO has completed national and international acquisitions of the following companies:
OURLabs, acquired by OPKO in December 2012, includes urologic, gastrointestinologic, dermapathologic, and women’s health laboratories based in Nashville, Tennessee. OURLabs operates 18 phlebotomy sites throughout the United States and is strategically positioned as OPKO’s commercial platform for the anticipated U.S. launch of 4Kscore™, a prostate cancer biomarker panel.
OPKO Diagnostics creates innovative point-of-care diagnostics technology that transition in-vitro medical diagnostics tests from the laboratory to the physician’s office and allow the performance of complex laboratory quality assays in minutes with no training and at minimal cost.
OPKO Chile markets, sells, and distributes pharmaceutical and nutraceutical products to private, hospital, and institutional markets in Chile.
OPKO EU develops, manufactures, markets, and sells a line of pharmaceutical, nutraceutical, and veterinary products throughout Europe.
OPKO FineTech develops specialty active pharmaceutical ingredients (APIs) in Israel.
OPKO Mexico manufactures, markets, sells, and distributes ophthalmic and other pharmaceutical products to private and public customers in Mexico.
OPKO continues to explore acquisition opportunities for complementary pharmaceuticals, compounds, technologies, and businesses. They expect their future growth to arise from leveraging our proprietary technology, development strengths, and pursuit of complementary and strategic acquisitions and investments.
Experienced Management Team:
OPKO has a highly experienced management team that has demonstrated an ability to successfully build and manage pharmaceutical businesses. OPKO’s Chairman and Chief Executive Officer, Dr. Phillip Frost, founded and served as Chairman and Chief Executive Officer of IVAX Corporation, a multi-national pharmaceutical company, from 1987 until the acquisition of IVAX by Teva Pharmaceutical Industries, Limited in January 2006. Dr. Frost currently serves as Chairman of the Board of Teva. Prior to Ivax, Dr. Frost founded and served as Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough Corporation in 1986. Other senior executive officers are also veterans in the pharmaceutical industry and have extensive development, regulatory, and commercialization expertise.
OPKO’s experienced management team has the development, regulatory, and commercialization expertise and relationships able to access and facilitate excellent commercial opportunities.
OPKO recent stock activity – CLICK HERE
For Investor Relations – CLICK HERE
Press Releases of Interest – CLICK HERE